Extrahepatic metabolism of ibrutinib Johannes J. M. RoodAmer JamalpoorRolf W. Sparidans PRECLINICAL STUDIES Open access 04 July 2020 Pages: 1 - 14
Hydroxyethylcellulose as a methotrexate carrier in anticancer therapy Jarosław CiekotMateusz PsurskiJanusz Boratyński PRECLINICAL STUDIES Open access 08 July 2020 Pages: 15 - 23
B7-H6 as an efficient target for T cell-induced cytotoxicity in haematologic malignant cells Xin SunJingyuan ZhaoMan Zhang PRECLINICAL STUDIES 07 August 2020 Pages: 24 - 33
Dual-function chimeric antigen receptor T cells targeting c-Met and PD-1 exhibit potent anti-tumor efficacy in solid tumors Xingxing YuanZujun SunMin Yu PRECLINICAL STUDIES 08 August 2020 Pages: 34 - 51
Analysis and identification of novel biomarkers involved in neuroblastoma via integrated bioinformatics Bo ChenPeng DingZhijie Li PRECLINICAL STUDIES 08 August 2020 Pages: 52 - 65
Development of a carrier system containing hyaluronic acid and protamine for siRNA delivery in the treatment of melanoma Jing YangRong ZhaoRui Wang PRECLINICAL STUDIES 13 August 2020 Pages: 66 - 76
Crizotinib induced antitumor activity and synergized with chemotherapy and hormonal drugs in breast cancer cells via downregulating MET and estrogen receptor levels Nehad M. AyoubDalia R. IbrahimBelal A. Al-Husein PRECLINICAL STUDIES 24 August 2020 Pages: 77 - 88
Effects of zinc porphyrin and zinc phthalocyanine derivatives in photodynamic anticancer therapy under different partial pressures of oxygen in vitro Martin PolaHana KolarovaRobert Bajgar PRECLINICAL STUDIES 24 August 2020 Pages: 89 - 97
Novel [l,2,4]triazolo[3,4-a]isoquinoline chalcones as new chemotherapeutic agents: Block IAP tyrosine kinase domain and induce both intrinsic and extrinsic pathways of apoptosis Magda F. MohamedFarid M. SroorIsmail A. Abdelhamid PRECLINICAL STUDIES 28 August 2020 Pages: 98 - 110
The anti-malaria agent artesunate exhibits cytotoxic effects in primary effusion lymphoma Chie IshikawaNaoki Mori PRECLINICAL STUDIES 03 September 2020 Pages: 111 - 121
Mitogen-activated protein kinases are involved in cucurbitacin D-induced antitumor effects on adult T-cell leukemia cells Duo WangMengyue ShenYasuhiro Yoshida PRECLINICAL STUDIES 10 September 2020 Pages: 122 - 130
Pancreatic cancer drug-sensitivity predicted by synergy of p53-Activator Wnt Inhibitor-2 (PAWI-2) and protein biomarker expression Jiongjia ChengJohn R. Cashman PRECLINICAL STUDIES 11 September 2020 Pages: 131 - 141
Phase I clinical trial of temozolomide and methoxyamine (TRC-102), an inhibitor of base excision repair, in patients with advanced solid tumors Jennifer R. EadsSmitha S. KrishnamurthiAfshin Dowlati PHASE I STUDIES 17 June 2020 Pages: 142 - 151
The safety and tolerability of epacadostat alone and in combination with pembrolizumab in patients with advanced solid tumors: results from a first-in-Japanese phase I study (KEYNOTE-434) Toshihiko DoiYutaka FujiwaraNoboru Yamamoto PHASE I STUDIES 20 June 2020 Pages: 152 - 162
A phase Ib open-label dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of cobimetinib (GDC-0973) and ipatasertib (GDC-0068) in patients with locally advanced or metastatic solid tumors Geoffrey I. ShapiroPatricia LoRussoJohanna C. Bendell PHASE I STUDIES 31 July 2020 Pages: 163 - 174
A phase I study of intraperitoneal paclitaxel combined with gemcitabine plus nab-paclitaxel for pancreatic cancer with peritoneal metastasis Naminatsu TakaharaYousuke NakaiKazuhiko Koike PHASE I STUDIES 08 August 2020 Pages: 175 - 181
Immunologic and tumor responses of pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in pancreatic ductal adenocarcinoma (PDAC) J. Randolph HechtKyriakos P. PapadopoulosAung Naing PHASE I STUDIES 10 September 2020 Pages: 182 - 192
Phase 1 study of 2 high dose intensity schedules of the pan-Notch inhibitor crenigacestat (LY3039478) in combination with prednisone in patients with advanced or metastatic cancer Analía AzaroCapucine BaldiniChristophe Massard PHASE I STUDIES 11 September 2020 Pages: 193 - 201
Phase I/II study of erlotinib plus S-1 for patients with previously treated non-small cell lung cancer: Thoracic Oncology Research Group (TORG) 0808/0913 Yoshiro NakaharaTsuneo ShimokawaHiroaki Okamoto PHASE II STUDIES Open access 15 August 2020 Pages: 202 - 209
Erlotinib and bevacizumab in elderly patients ≥75 years old with non-small cell lung cancer harboring epidermal growth factor receptor mutations Yoichiro AoshimaMasato KarayamaTakafumi Suda PHASE II STUDIES 17 August 2020 Pages: 210 - 216
Efficacy of the eribulin, pertuzumab, and trastuzumab combination therapy for human epidermal growth factor receptor 2–positive advanced or metastatic breast cancer: a multicenter, single arm, phase II study (JBCRG-M03 study) Toshinari YamashitaHidetoshi KawaguchiMasakazu Toi PHASE II STUDIES Open access 24 August 2020 Pages: 217 - 225
Atorvastatin in combination with radiotherapy and temozolomide for glioblastoma: a prospective phase II study Abdullah K. AltwairgiWaleed A. AlghareebAbdullah A. Alsharm PHASE II STUDIES 27 August 2020 Pages: 226 - 231
Successful treatment of an osimertinib-resistant lung adenocarcinoma with an exon 18 EGFR mutation (G719S) with afatinib plus bevacizumab Motohiro TamiyaKei KunimasaToru Kumagai Short Report 18 June 2020 Pages: 232 - 236
Acute tubulointerstitial nephritis induced by the tyrosine kinase inhibitor vandetanib Melissa Pilco TeranAna Merino RibasJordi Calabia Martínez Short Report 09 July 2020 Pages: 237 - 239
Subcellular distribution and mechanism of action of AL906, a novel and potent EGFR inhibitor rationally designed to be green fluorescent Nahid GolabiAnne-Laure LarroqueBertrand J. Jean-Claude Short Report 09 July 2020 Pages: 240 - 250
Anti-transcriptional intermediary factor 1-γ antibody-positive dermatomyositis induced by nivolumab for lung adenocarcinoma: A case report Megumu OsakiRyo TachikawaKeisuke Tomii Short Report 10 July 2020 Pages: 251 - 255
The proportion of North American cancer trials that evaluate novel targets Eli GumnitAden C. FeustelJonathan Kimmelman Short Report 18 July 2020 Pages: 256 - 259
Real-world systemic sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Korea Min Jin LeeSung Won ChangJae Young Jang Short Report 04 August 2020 Pages: 260 - 268
Atezolizumab plus carboplatin and etoposide in small cell lung cancer patients previously treated with platinum-based chemotherapy Hidenobu IshiiKoichi AzumaTomoaki Hoshino Short Report 11 August 2020 Pages: 269 - 271
Serum concentration of the CKD4/6 inhibitor abemaciclib, but not of creatinine, strongly predicts hematological adverse events in patients with breast cancer: a preliminary report Akimitsu MaedaKei IrieMasataka Sawaki Short Report 27 August 2020 Pages: 272 - 277
A novel LRRFIP1-ALK fusion in inflammatory myofibroblastic tumor of hip and response to crizotinib Weifeng LiuQianqian DuanXiaohui Niu Short Report 11 September 2020 Pages: 278 - 282
Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma Frank KroschinskyJan Moritz MiddekeNorbert Schmitz Correction 31 May 2020 Pages: 283 - 284
Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B cell non-Hodgkin lymphoma Frank KroschinskyJan Moritz MiddekeNorbert Schmitz Correction 23 June 2020 Pages: 285 - 286
Correction to: Germinal Immunogenetics predict treatment outcome for PD-1/PD-L1 checkpoint inhibitors Sadal RefaeJocelyn GalEsma Saada-Bouzid Correction 04 June 2020 Pages: 287 - 292
RETRACTED ARTICLE: A novel small-molecule inhibitor suppresses colon cancer metastasis through inhibition of metastasis-associated in colon cancer-1 transcription Xue-Feng JiangZhen TianYu Sun PRECLINICAL STUDIES 04 June 2020 Pages: 293 - 293
